APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ondansetron

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. It is marketed predominantly as the racemate. The free-base molecular formula is C18H19N3O (molecular weight 293.36 g/mol). A commonly used systematic chemical name is (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; commercial products are frequently supplied as ondansetron hydrochloride (often with defined hydration state) to improve handling and aqueous solubility in finished dosage forms.

From a physicochemical standpoint, ondansetron is a weakly basic heteroaromatic ketone (imidazole nitrogen as the principal basic site), typically encountered as an off-white crystalline solid. The free base is sparingly soluble in water with moderate lipophilicity (logP in the low-to-mid single digits), while the hydrochloride salt is substantially more water-soluble and therefore preferred for oral solutions and injectables. Industrial synthesis is generally executed by constructing the carbazol-4-one core (via stepwise ring-forming cyclization on a suitably substituted bicyclic precursor), introducing a 3-(halomethyl) or equivalent electrophilic handle, then performing N-alkylation of 2-methylimidazole to install the imidazolylmethyl side chain; the active base is finally converted to the hydrochloride (and, where applicable, crystallized to a controlled hydrate) under tightly controlled crystallization and polymorph control conditions.

Pharmacologically, ondansetron is a potent and selective antagonist of the 5-HT3 ligand-gated ion channel, blocking serotonin-mediated signaling on peripheral vagal afferents in the gastrointestinal tract and centrally within the chemoreceptor trigger zone and vomiting center, thereby suppressing the emetogenic reflex without relying on dopamine D2 receptor blockade. After oral administration, systemic exposure is limited by first-pass metabolism and shows moderate bioavailability; peak concentrations typically occur within a few hours. Distribution is extensive with moderate plasma protein binding. Clearance is predominantly hepatic oxidative metabolism (CYP3A4 as a major contributor, with CYP2D6 and CYP1A2 also participating), with metabolites eliminated in urine and feces and only a minor fraction recovered unchanged; the terminal half-life in healthy adults is on the order of several hours and is meaningfully prolonged in hepatic impairment, which is the clinically relevant driver for dose limitation in that population.

The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.

What turns activity into demand

Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.

The commercial boundary

For Ondansetron, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.

Which conditions determine usable ondansetron performance?

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.

Selected research

Market Analysis & Forecast

Global Ondansetron Market Analysis and Forecast 2026-2032

15 January 2026217 pages

Choose your research edition.

Industry ResearchOndansetron Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Ondansetron Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Ondansetron Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ondansetron Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Ondansetron Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. It is marketed predominantly as the racemate. The free-base molecular formula is C18H19N3O (molecular weight 293.36 g/mol). A commonly used systematic chemical name is (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; commercial products are frequently supplied as ondansetron hydrochloride (often with defined hydration state) to improve handling and aqueous solubility in finished dosage forms.

From a physicochemical standpoint, ondansetron is a weakly basic heteroaromatic ketone (imidazole nitrogen as the principal basic site), typically encountered as an off-white crystalline solid. The free base is sparingly soluble in water with moderate lipophilicity (logP in the low-to-mid single digits), while the hydrochloride salt is substantially more water-soluble and therefore preferred for oral solutions and injectables. Industrial synthesis is generally executed by constructing the carbazol-4-one core (via stepwise ring-forming cyclization on a suitably substituted bicyclic precursor), introducing a 3-(halomethyl) or equivalent electrophilic handle, then performing N-alkylation of 2-methylimidazole to install the imidazolylmethyl side chain; the active base is finally converted to the hydrochloride (and, where applicable, crystallized to a controlled hydrate) under tightly controlled crystallization and polymorph control conditions.

Pharmacologically, ondansetron is a potent and selective antagonist of the 5-HT3 ligand-gated ion channel, blocking serotonin-mediated signaling on peripheral vagal afferents in the gastrointestinal tract and centrally within the chemoreceptor trigger zone and vomiting center, thereby suppressing the emetogenic reflex without relying on dopamine D2 receptor blockade. After oral administration, systemic exposure is limited by first-pass metabolism and shows moderate bioavailability; peak concentrations typically occur within a few hours. Distribution is extensive with moderate plasma protein binding. Clearance is predominantly hepatic oxidative metabolism (CYP3A4 as a major contributor, with CYP2D6 and CYP1A2 also participating), with metabolites eliminated in urine and feces and only a minor fraction recovered unchanged; the terminal half-life in healthy adults is on the order of several hours and is meaningfully prolonged in hepatic impairment, which is the clinically relevant driver for dose limitation in that population.

Read the full market overview

The global Ondansetron market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Ondansetron is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Ondansetron is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Asia-Pacific market for Ondansetron is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Ondansetron is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Ondansetron include Sun Pharmaceuticals, Sandoz, Qilu Pharmaceutical, Fuan Pharmaceutical, PKU HealthCare, Wockhardt, Aelida Healthcare, Beijing Sciecure Pharmaceutical and Jiangsu Hengrui Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Ondansetron, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Ondansetron, also provides the sales of main regions and countries. Of the upcoming market potential for Ondansetron, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ondansetron sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Ondansetron market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Ondansetron sales, projected growth trends, production technology, application and end-user industry.

Ondansetron Segment by Company

Sun Pharmaceuticals

Sandoz

Qilu Pharmaceutical

Fuan Pharmaceutical

PKU HealthCare

Wockhardt

Aelida Healthcare

Beijing Sciecure Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Fosun Pharma

Harbin Medisan

CTX Lifesciences

Pfizer

Viatris

Dr. Reddy's Laboratories

Aurobindo Pharma

Zydus Lifesciences

Lupin

Hikma Pharmaceuticals

Fresenius Kabi

Baxter Pharmaceuticals

Ondansetron Segment by Type

Tablets (including ODT)

Injection

ODF/OSF

Other

Ondansetron Segment by Application

Hospital pharmacies

Retail pharmacies

Online pharmacies

Ondansetron Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ondansetron market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ondansetron and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ondansetron.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Ondansetron in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Ondansetron manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ondansetron sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Ondansetron Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Tablets (including ODT) Major Manufacturers Table 3. Injection Major Manufacturers Table 4. ODF/OSF Major Manufacturers Table 5. Other Major Manufacturers Table 6. Global Ondansetron Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital pharmacies Major Manufacturers Table 8. Retail pharmacies Major Manufacturers Table 9. Online pharmacies Major Manufacturers Table 10. Ondansetron Industry Trends Table 11. Ondansetron Industry Drivers Table 12. Ondansetron Industry Opportunities and Challenges Table 13. Ondansetron Industry Restraints Table 14. Global Ondansetron Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Ondansetron Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Ondansetron Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Ondansetron Revenue Market Share by Region (2021-2026) Table 18. Global Ondansetron Revenue Market Share by Region (2027-2032) Table 19. Global Ondansetron Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (kg) Table 20. Global Ondansetron Sales by Region (2021-2026) & (kg) Table 21. Global Ondansetron Sales by Region (2027-2032) & (kg) Table 22. Global Ondansetron Sales Market Share by Region (2021-2026) Table 23. Global Ondansetron Sales Market Share by Region (2027-2032) Table 24. Global Ondansetron Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Ondansetron Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Ondansetron Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Ondansetron Sales Market Share by Manufacturers (2021-2026) Table 28. Global Ondansetron Sales Price (USD/g) of Manufacturers (2021-2026) Table 29. Global Ondansetron Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Ondansetron Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Ondansetron Manufacturers, Product Type & Application Table 32. Global Ondansetron Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Ondansetron by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Ondansetron Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Ondansetron Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Ondansetron Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Ondansetron Revenue Market Share by Type (2021-2026) Table 39. Global Ondansetron Revenue Market Share by Type (2027-2032) Table 40. Global Ondansetron Sales by Type 2021 VS 2025 VS 2032 (kg) Table 41. Global Ondansetron Sales by Type (2021-2026) & (kg) Table 42. Global Ondansetron Sales by Type (2027-2032) & (kg) Table 43. Global Ondansetron Sales Market Share by Type (2021-2026) Table 44. Global Ondansetron Sales Market Share by Type (2027-2032) Table 45. Global Ondansetron Price by Type (2021-2026) & (USD/g) Table 46. Global Ondansetron Price by Type (2027-2032) & (USD/g) Table 47. Global Ondansetron Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Ondansetron Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Ondansetron Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Ondansetron Revenue Market Share by Application (2021-2026) Table 51. Global Ondansetron Revenue Market Share by Application (2027-2032) Table 52. Global Ondansetron Sales by Application 2021 VS 2025 VS 2032 (kg) Table 53. Global Ondansetron Sales by Application (2021-2026) & (kg) Table 54. Global Ondansetron Sales by Application (2027-2032) & (kg) Table 55. Global Ondansetron Sales Market Share by Application (2021-2026) Table 56. Global Ondansetron Sales Market Share by Application (2027-2032) Table 57. Global Ondansetron Price by Application (2021-2026) & (USD/g) Table 58. Global Ondansetron Price by Application (2027-2032) & (USD/g) Table 59. Sun Pharmaceuticals Company Information Table 60. Sun Pharmaceuticals Business Overview Table 61. Sun Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 62. Sun Pharmaceuticals Ondansetron Product Portfolio Table 63. Sun Pharmaceuticals Recent Development Table 64. Sandoz Company Information Table 65. Sandoz Business Overview Table 66. Sandoz Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 67. Sandoz Ondansetron Product Portfolio Table 68. Sandoz Recent Development Table 69. Qilu Pharmaceutical Company Information Table 70. Qilu Pharmaceutical Business Overview Table 71. Qilu Pharmaceutical Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 72. Qilu Pharmaceutical Ondansetron Product Portfolio Table 73. Qilu Pharmaceutical Recent Development Table 74. Fuan Pharmaceutical Company Information Table 75. Fuan Pharmaceutical Business Overview Table 76. Fuan Pharmaceutical Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 77. Fuan Pharmaceutical Ondansetron Product Portfolio Table 78. Fuan Pharmaceutical Recent Development Table 79. PKU HealthCare Company Information Table 80. PKU HealthCare Business Overview Table 81. PKU HealthCare Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 82. PKU HealthCare Ondansetron Product Portfolio Table 83. PKU HealthCare Recent Development Table 84. Wockhardt Company Information Table 85. Wockhardt Business Overview Table 86. Wockhardt Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 87. Wockhardt Ondansetron Product Portfolio Table 88. Wockhardt Recent Development Table 89. Aelida Healthcare Company Information Table 90. Aelida Healthcare Business Overview Table 91. Aelida Healthcare Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 92. Aelida Healthcare Ondansetron Product Portfolio Table 93. Aelida Healthcare Recent Development Table 94. Beijing Sciecure Pharmaceutical Company Information Table 95. Beijing Sciecure Pharmaceutical Business Overview Table 96. Beijing Sciecure Pharmaceutical Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 97. Beijing Sciecure Pharmaceutical Ondansetron Product Portfolio Table 98. Beijing Sciecure Pharmaceutical Recent Development Table 99. Jiangsu Hengrui Pharmaceuticals Company Information Table 100. Jiangsu Hengrui Pharmaceuticals Business Overview Table 101. Jiangsu Hengrui Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 102. Jiangsu Hengrui Pharmaceuticals Ondansetron Product Portfolio Table 103. Jiangsu Hengrui Pharmaceuticals Recent Development Table 104. Fosun Pharma Company Information Table 105. Fosun Pharma Business Overview Table 106. Fosun Pharma Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 107. Fosun Pharma Ondansetron Product Portfolio Table 108. Fosun Pharma Recent Development Table 109. Harbin Medisan Company Information Table 110. Harbin Medisan Business Overview Table 111. Harbin Medisan Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 112. Harbin Medisan Ondansetron Product Portfolio Table 113. Harbin Medisan Recent Development Table 114. CTX Lifesciences Company Information Table 115. CTX Lifesciences Business Overview Table 116. CTX Lifesciences Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 117. CTX Lifesciences Ondansetron Product Portfolio Table 118. CTX Lifesciences Recent Development Table 119. Pfizer Company Information Table 120. Pfizer Business Overview Table 121. Pfizer Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 122. Pfizer Ondansetron Product Portfolio Table 123. Pfizer Recent Development Table 124. Viatris Company Information Table 125. Viatris Business Overview Table 126. Viatris Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 127. Viatris Ondansetron Product Portfolio Table 128. Viatris Recent Development Table 129. Dr. Reddy's Laboratories Company Information Table 130. Dr. Reddy's Laboratories Business Overview Table 131. Dr. Reddy's Laboratories Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 132. Dr. Reddy's Laboratories Ondansetron Product Portfolio Table 133. Dr. Reddy's Laboratories Recent Development Table 134. Aurobindo Pharma Company Information Table 135. Aurobindo Pharma Business Overview Table 136. Aurobindo Pharma Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 137. Aurobindo Pharma Ondansetron Product Portfolio Table 138. Aurobindo Pharma Recent Development Table 139. Zydus Lifesciences Company Information Table 140. Zydus Lifesciences Business Overview Table 141. Zydus Lifesciences Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 142. Zydus Lifesciences Ondansetron Product Portfolio Table 143. Zydus Lifesciences Recent Development Table 144. Lupin Company Information Table 145. Lupin Business Overview Table 146. Lupin Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 147. Lupin Ondansetron Product Portfolio Table 148. Lupin Recent Development Table 149. Hikma Pharmaceuticals Company Information Table 150. Hikma Pharmaceuticals Business Overview Table 151. Hikma Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 152. Hikma Pharmaceuticals Ondansetron Product Portfolio Table 153. Hikma Pharmaceuticals Recent Development Table 154. Fresenius Kabi Company Information Table 155. Fresenius Kabi Business Overview Table 156. Fresenius Kabi Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 157. Fresenius Kabi Ondansetron Product Portfolio Table 158. Fresenius Kabi Recent Development Table 159. Baxter Pharmaceuticals Company Information Table 160. Baxter Pharmaceuticals Business Overview Table 161. Baxter Pharmaceuticals Ondansetron Sales (kg), Revenue (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 162. Baxter Pharmaceuticals Ondansetron Product Portfolio Table 163. Baxter Pharmaceuticals Recent Development Table 164. North America Ondansetron Revenue by Type (2021-2026) & (US$ Million) Table 165. North America Ondansetron Revenue by Type (2027-2032) & (US$ Million) Table 166. North America Ondansetron Sales by Type (2021-2026) & (kg) Table 167. North America Ondansetron Sales by Type (2027-2032) & (kg) Table 168. North America Ondansetron Sales Price by Type (2021-2026) & (USD/g) Table 169. North America Ondansetron Sales Price by Type (2027-2032) & (USD/g) Table 170. North America Ondansetron Revenue by Application (2021-2026) & (US$ Million) Table 171. North America Ondansetron Revenue by Application (2027-2032) & (US$ Million) Table 172. North America Ondansetron Sales by Application (2021-2026) & (kg) Table 173. North America Ondansetron Sales by Application (2027-2032) & (kg) Table 174. North America Ondansetron Sales Price by Application (2021-2026) & (USD/g) Table 175. North America Ondansetron Sales Price by Application (2027-2032) & (USD/g) Table 176. North America Ondansetron Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 177. North America Ondansetron Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 178. North America Ondansetron Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 179. North America Ondansetron Sales by Country (2021 VS 2025 VS 2032) & (kg) Table 180. North America Ondansetron Sales by Country (2021-2026) & (kg) Table 181. North America Ondansetron Sales by Country (2027-2032) & (kg) Table 182. North America Ondansetron Sales Price by Country (2021-2026) & (USD/g) Table 183. North America Ondansetron Sales Price by Country (2027-2032) & (USD/g) Table 184. United States Ondansetron Revenue (2021-2032) & (US$ Million) Table 185. Canada Ondansetron Revenue (2021-2032) & (US$ Million) Table 186. Mexico Ondansetron Revenue (2021-2032) & (US$ Million) Table 187. Europe Ondansetron Revenue by Type (2021-2026) & (US$ Million) Table 188. Europe Ondansetron Revenue by Type (2027-2032) & (US$ Million) Table 189. Europe Ondansetron Sales by Type (2021-2026) & (kg) Table 190. Europe Ondansetron Sales by Type (2027-2032) & (kg) Table 191. Europe Ondansetron Sales Price by Type (2021-2026) & (USD/g) Table 192. Europe Ondansetron Sales Price by Type (2027-2032) & (USD/g) Table 193. Europe Ondansetron Revenue by Application (2021-2026) & (US$ Million) Table 194. Europe Ondansetron Revenue by Application (2027-2032) & (US$ Million) Table 195. Europe Ondansetron Sales by Application (2021-2026) & (kg) Table 196. Europe Ondansetron Sales by Application (2027-2032) & (kg) Table 197. Europe Ondansetron Sales Price by Application (2021-2026) & (USD/g) Table 198. Europe Ondansetron Sales Price by Application (2027-2032) & (USD/g) Table 199. Europe Ondansetron Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. Europe Ondansetron Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. Europe Ondansetron Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. Europe Ondansetron Sales by Country (2021 VS 2025 VS 2032) & (kg) Table 203. Europe Ondansetron Sales by Country (2021-2026) & (kg) Table 204. Europe Ondansetron Sales by Country (2027-2032) & (kg) Table 205. Europe Ondansetron Sales Price by Country (2021-2026) & (USD/g) Table 206. Europe Ondansetron Sales Price by Country (2027-2032) & (USD/g) Table 207. Germany Ondansetron Revenue (2021-2032) & (US$ Million) Table 208. France Ondansetron Revenue (2021-2032) & (US$ Million) Table 209. U.K. Ondansetron Revenue (2021-2032) & (US$ Million) Table 210. Italy Ondansetron Revenue (2021-2032) & (US$ Million) Table 211. Russia Ondansetron Revenue (2021-2032) & (US$ Million) Table 212. Spain Ondansetron Revenue (2021-2032) & (US$ Million) Table 213. Netherlands Ondansetron Revenue (2021-2032) & (US$ Million) Table 214. Switzerland Ondansetron Revenue (2021-2032) & (US$ Million) Table 215. Sweden Ondansetron Revenue (2021-2032) & (US$ Million) Table 216. Poland Ondansetron Revenue (2021-2032) & (US$ Million) Table 217. China Ondansetron Revenue by Type (2021-2026) & (US$ Million) Table 218. China Ondansetron Revenue by Type (2027-2032) & (US$ Million) Table 219. China Ondansetron Sales by Type (2021-2026) & (kg) Table 220. China Ondansetron Sales by Type (2027-2032) & (kg) Table 221. China Ondansetron Sales Price by Type (2021-2026) & (USD/g) Table 222. China Ondansetron Sales Price by Type (2027-2032) & (USD/g) Table 223. China Ondansetron Revenue by Application (2021-2026) & (US$ Million) Table 224. China Ondansetron Revenue by Application (2027-2032) & (US$ Million) Table 225. China Ondansetron Sales by Application (2021-2026) & (kg) Table 226. China Ondansetron Sales by Application (2027-2032) & (kg) Table 227. China Ondansetron Sales Price by Application (2021-2026) & (USD/g) Table 228. China Ondansetron Sales Price by Application (2027-2032) & (USD/g) Table 229. Asia Ondansetron Revenue by Type (2021-2026) & (US$ Million) Table 230. Asia Ondansetron Revenue by Type (2027-2032) & (US$ Million) Table 231. Asia Ondansetron Sales by Type (2021-2026) & (kg) Table 232. Asia Ondansetron Sales by Type (2027-2032) & (kg) Table 233. Asia Ondansetron Sales Price by Type (2021-2026) & (USD/g) Table 234. Asia Ondansetron Sales Price by Type (2027-2032) & (USD/g) Table 235. Asia Ondansetron Revenue by Application (2021-2026) & (US$ Million) Table 236. Asia Ondansetron Revenue by Application (2027-2032) & (US$ Million) Table 237. Asia Ondansetron Sales by Application (2021-2026) & (kg) Table 238. Asia Ondansetron Sales by Application (2027-2032) & (kg) Table 239. Asia Ondansetron Sales Price by Application (2021-2026) & (USD/g) Table 240. Asia Ondansetron Sales Price by Application (2027-2032) & (USD/g) Table 241. Asia Ondansetron Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 242. Asia Ondansetron Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 243. Asia Ondansetron Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 244. Asia Ondansetron Sales by Country (2021 VS 2025 VS 2032) & (kg) Table 245. Asia Ondansetron Sales by Country (2021-2026) & (kg) Table 246. Asia Ondansetron Sales by Country (2027-2032) & (kg) Table 247. Asia Ondansetron Sales Price by Country (2021-2026) & (USD/g) Table 248. Asia Ondansetron Sales Price by Country (2027-2032) & (USD/g) Table 249. Japan Ondansetron Revenue (2021-2032) & (US$ Million) Table 250. South Korea Ondansetron Revenue (2021-2032) & (US$ Million) Table 251. India Ondansetron Revenue (2021-2032) & (US$ Million) Table 252. Australia Ondansetron Revenue (2021-2032) & (US$ Million) Table 253. Taiwan Ondansetron Revenue (2021-2032) & (US$ Million) Table 254. Southeast Asia Ondansetron Revenue (2021-2032) & (US$ Million) Table 255. SAMEA Ondansetron Revenue by Type (2021-2026) & (US$ Million) Table 256. SAMEA Ondansetron Revenue by Type (2027-2032) & (US$ Million) Table 257. SAMEA Ondansetron Sales by Type (2021-2026) & (kg) Table 258. SAMEA Ondansetron Sales by Type (2027-2032) & (kg) Table 259. SAMEA Ondansetron Sales Price by Type (2021-2026) & (USD/g) Table 260. SAMEA Ondansetron Sales Price by Type (2027-2032) & (USD/g) Table 261. SAMEA Ondansetron Revenue by Application (2021-2026) & (US$ Million) Table 262. SAMEA Ondansetron Revenue by Application (2027-2032) & (US$ Million) Table 263. SAMEA Ondansetron Sales by Application (2021-2026) & (kg) Table 264. SAMEA Ondansetron Sales by Application (2027-2032) & (kg) Table 265. SAMEA Ondansetron Sales Price by Application (2021-2026) & (USD/g) Table 266. SAMEA Ondansetron Sales Price by Application (2027-2032) & (USD/g) Table 267. SAMEA Ondansetron Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 268. SAMEA Ondansetron Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 269. SAMEA Ondansetron Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 270. SAMEA Ondansetron Sales by Country (2021 VS 2025 VS 2032) & (kg) Table 271. SAMEA Ondansetron Sales by Country (2021-2026) & (kg) Table 272. SAMEA Ondansetron Sales by Country (2027-2032) & (kg) Table 273. SAMEA Ondansetron Sales Price by Country (2021-2026) & (USD/g) Table 274. SAMEA Ondansetron Sales Price by Country (2027-2032) & (USD/g) Table 275. Brazil Ondansetron Revenue (2021-2032) & (US$ Million) Table 276. Argentina Ondansetron Revenue (2021-2032) & (US$ Million) Table 277. Chile Ondansetron Revenue (2021-2032) & (US$ Million) Table 278. Colombia Ondansetron Revenue (2021-2032) & (US$ Million) Table 279. Peru Ondansetron Revenue (2021-2032) & (US$ Million) Table 280. Saudi Arabia Ondansetron Revenue (2021-2032) & (US$ Million) Table 281. Israel Ondansetron Revenue (2021-2032) & (US$ Million) Table 282. UAE Ondansetron Revenue (2021-2032) & (US$ Million) Table 283. Turkey Ondansetron Revenue (2021-2032) & (US$ Million) Table 284. Iran Ondansetron Revenue (2021-2032) & (US$ Million) Table 285. Egypt Ondansetron Revenue (2021-2032) & (US$ Million) Table 286. Key Raw Materials Table 287. Raw Materials Key Suppliers Table 288. Ondansetron Distributors List Table 289. Ondansetron Customers List Table 290. Research Programs/Design for This Report Table 291. Authors List of This Report Table 292. Secondary Sources Table 293. Primary Sources List of Figures Figure 1. Ondansetron Image Figure 2. Global Ondansetron Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ondansetron Market Size Share 2021 VS 2025 VS 2032 Figure 4. Tablets (including ODT) Image Figure 5. Injection Image Figure 6. ODF/OSF Image Figure 7. Other Image Figure 8. Global Ondansetron Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Ondansetron Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital pharmacies Image Figure 11. Retail pharmacies Image Figure 12. Online pharmacies Image Figure 13. Global Ondansetron Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Ondansetron Revenue (2021-2032) & (US$ Million) Figure 15. Global Ondansetron Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Ondansetron Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Ondansetron Revenue Market Share by Region (2021-2032) Figure 18. Global Ondansetron Sales (2021-2032) & (kg) Figure 19. Global Ondansetron Sales by Region: 2021 VS 2025 VS 2032 (kg) Figure 20. Global Ondansetron Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Ondansetron Sales YoY (2021-2032) & (kg) Figure 22. Europe Ondansetron Sales YoY (2021-2032) & (kg) Figure 23. China Ondansetron Sales YoY (2021-2032) & (kg) Figure 24. Asia (Excluding China) Ondansetron Sales YoY (2021-2032) & (kg) Figure 25. South America, Middle East and Africa Ondansetron Sales YoY (2021-2032) & (kg) Figure 26. Global Ondansetron Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Ondansetron Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Ondansetron Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Ondansetron Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Ondansetron Revenue Market Share by Type (2021-2032) Figure 32. Global Ondansetron Sales by Type (2021 VS 2025 VS 2032) & (kg) Figure 33. Global Ondansetron Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Ondansetron Sales Market Share by Type (2021-2032) Figure 35. Global Ondansetron Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Ondansetron Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Ondansetron Revenue Market Share by Application (2021-2032) Figure 38. Global Ondansetron Sales by Application (2021 VS 2025 VS 2032) & (kg) Figure 39. Global Ondansetron Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Ondansetron Sales Market Share by Application (2021-2032) Figure 41. North America Ondansetron Revenue Share by Type (2021-2032) Figure 42. North America Ondansetron Sales Share by Type (2021-2032) Figure 43. North America Ondansetron Revenue Share by Application (2021-2032) Figure 44. North America Ondansetron Sales Share by Application (2021-2032) Figure 45. North America Ondansetron Revenue Share by Country (2021-2032) Figure 46. North America Ondansetron Sales Share by Country (2021-2032) Figure 47. Europe Ondansetron Revenue Share by Type (2021-2032) Figure 48. Europe Ondansetron Sales Share by Type (2021-2032) Figure 49. Europe Ondansetron Revenue Share by Application (2021-2032) Figure 50. Europe Ondansetron Sales Share by Application (2021-2032) Figure 51. Europe Ondansetron Revenue Share by Country (2021-2032) Figure 52. Europe Ondansetron Sales Share by Country (2021-2032) Figure 53. China Ondansetron Revenue Share by Type (2021-2032) Figure 54. China Ondansetron Sales Share by Type (2021-2032) Figure 55. China Ondansetron Revenue Share by Application (2021-2032) Figure 56. China Ondansetron Sales Share by Application (2021-2032) Figure 57. Asia Ondansetron Revenue Share by Type (2021-2032) Figure 58. Asia Ondansetron Sales Share by Type (2021-2032) Figure 59. Asia Ondansetron Revenue Share by Application (2021-2032) Figure 60. Asia Ondansetron Sales Share by Application (2021-2032) Figure 61. Asia Ondansetron Revenue Share by Country (2021-2032) Figure 62. Asia Ondansetron Sales Share by Country (2021-2032) Figure 63. SAMEA Ondansetron Revenue Share by Type (2021-2032) Figure 64. SAMEA Ondansetron Sales Share by Type (2021-2032) Figure 65. SAMEA Ondansetron Revenue Share by Application (2021-2032) Figure 66. SAMEA Ondansetron Sales Share by Application (2021-2032) Figure 67. SAMEA Ondansetron Revenue Share by Country (2021-2032) Figure 68. SAMEA Ondansetron Sales Share by Country (2021-2032) Figure 69. Ondansetron Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Ondansetron Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets (including ODT)
  • Injection
  • ODF/OSF
  • Other
Applications
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
Companies covered
  • Sun Pharmaceuticals
  • Sandoz
  • Qilu Pharmaceutical
  • Fuan Pharmaceutical
  • PKU HealthCare
  • Wockhardt
  • Aelida Healthcare
  • Beijing Sciecure Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Fosun Pharma
  • Harbin Medisan
  • CTX Lifesciences
  • Pfizer
  • Viatris
  • Dr. Reddy's Laboratories
  • Aurobindo Pharma
  • Zydus Lifesciences
  • Lupin
  • Hikma Pharmaceuticals
  • Fresenius Kabi
  • Baxter Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Ondansetron Market by Type
  3. 1.2.1 Global Ondansetron Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Tablets (including ODT)
  5. 1.2.3 Injection
  6. 1.2.4 ODF/OSF
  7. 1.2.5 Other
  8. 1.3 Ondansetron Market by Application
  9. 1.3.1 Global Ondansetron Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital pharmacies
  11. 1.3.3 Retail pharmacies
  12. 1.3.4 Online pharmacies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Ondansetron Market Dynamics
  1. 2.1 Ondansetron Industry Trends
  2. 2.2 Ondansetron Industry Drivers
  3. 2.3 Ondansetron Industry Opportunities and Challenges
  4. 2.4 Ondansetron Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Ondansetron Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Ondansetron Revenue by Region
  3. 3.2.1 Global Ondansetron Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Ondansetron Revenue by Region (2021-2026)
  5. 3.2.3 Global Ondansetron Revenue by Region (2027-2032)
  6. 3.2.4 Global Ondansetron Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Ondansetron Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Ondansetron Sales by Region
  9. 3.4.1 Global Ondansetron Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Ondansetron Sales by Region (2021-2026)
  11. 3.4.3 Global Ondansetron Sales by Region (2027-2032)
  12. 3.4.4 Global Ondansetron Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Ondansetron Revenue by Manufacturers
  2. 4.1.1 Global Ondansetron Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Ondansetron Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Ondansetron Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Ondansetron Sales by Manufacturers
  6. 4.2.1 Global Ondansetron Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Ondansetron Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Ondansetron Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Ondansetron Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Ondansetron Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Ondansetron Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Ondansetron Manufacturers, Product Type & Application
  13. 4.7 Global Ondansetron Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Ondansetron Market CR5 and HHI
  16. 4.8.2 2025 Ondansetron Tier 1, Tier 2, and Tier 3
5 Ondansetron Market by Type
  1. 5.1 Global Ondansetron Revenue by Type
  2. 5.1.1 Global Ondansetron Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Ondansetron Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Ondansetron Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Ondansetron Sales by Type
  6. 5.2.1 Global Ondansetron Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Ondansetron Sales by Type (2021-2032) & (kg)
  8. 5.2.3 Global Ondansetron Sales Market Share by Type (2021-2032)
  9. 5.3 Global Ondansetron Price by Type
6 Ondansetron Market by Application
  1. 6.1 Global Ondansetron Revenue by Application
  2. 6.1.1 Global Ondansetron Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Ondansetron Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Ondansetron Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Ondansetron Sales by Application
  6. 6.2.1 Global Ondansetron Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Ondansetron Sales by Application (2021-2032) & (kg)
  8. 6.2.3 Global Ondansetron Sales Market Share by Application (2021-2032)
  9. 6.3 Global Ondansetron Price by Application
7 Company Profiles
  1. 7.1 Sun Pharmaceuticals
  2. 7.1.1 Sun Pharmaceuticals Company Information
  3. 7.1.2 Sun Pharmaceuticals Business Overview
  4. 7.1.3 Sun Pharmaceuticals Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sun Pharmaceuticals Ondansetron Product Portfolio
  6. 7.1.5 Sun Pharmaceuticals Recent Developments
  7. 7.2 Sandoz
  8. 7.2.1 Sandoz Company Information
  9. 7.2.2 Sandoz Business Overview
  10. 7.2.3 Sandoz Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sandoz Ondansetron Product Portfolio
  12. 7.2.5 Sandoz Recent Developments
  13. 7.3 Qilu Pharmaceutical
  14. 7.3.1 Qilu Pharmaceutical Company Information
  15. 7.3.2 Qilu Pharmaceutical Business Overview
  16. 7.3.3 Qilu Pharmaceutical Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Qilu Pharmaceutical Ondansetron Product Portfolio
  18. 7.3.5 Qilu Pharmaceutical Recent Developments
  19. 7.4 Fuan Pharmaceutical
  20. 7.4.1 Fuan Pharmaceutical Company Information
  21. 7.4.2 Fuan Pharmaceutical Business Overview
  22. 7.4.3 Fuan Pharmaceutical Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Fuan Pharmaceutical Ondansetron Product Portfolio
  24. 7.4.5 Fuan Pharmaceutical Recent Developments
  25. 7.5 PKU HealthCare
  26. 7.5.1 PKU HealthCare Company Information
  27. 7.5.2 PKU HealthCare Business Overview
  28. 7.5.3 PKU HealthCare Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 PKU HealthCare Ondansetron Product Portfolio
  30. 7.5.5 PKU HealthCare Recent Developments
  31. 7.6 Wockhardt
  32. 7.6.1 Wockhardt Company Information
  33. 7.6.2 Wockhardt Business Overview
  34. 7.6.3 Wockhardt Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Wockhardt Ondansetron Product Portfolio
  36. 7.6.5 Wockhardt Recent Developments
  37. 7.7 Aelida Healthcare
  38. 7.7.1 Aelida Healthcare Company Information
  39. 7.7.2 Aelida Healthcare Business Overview
  40. 7.7.3 Aelida Healthcare Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Aelida Healthcare Ondansetron Product Portfolio
  42. 7.7.5 Aelida Healthcare Recent Developments
  43. 7.8 Beijing Sciecure Pharmaceutical
  44. 7.8.1 Beijing Sciecure Pharmaceutical Company Information
  45. 7.8.2 Beijing Sciecure Pharmaceutical Business Overview
  46. 7.8.3 Beijing Sciecure Pharmaceutical Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Beijing Sciecure Pharmaceutical Ondansetron Product Portfolio
  48. 7.8.5 Beijing Sciecure Pharmaceutical Recent Developments
  49. 7.9 Jiangsu Hengrui Pharmaceuticals
  50. 7.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 7.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 7.9.3 Jiangsu Hengrui Pharmaceuticals Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Jiangsu Hengrui Pharmaceuticals Ondansetron Product Portfolio
  54. 7.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 7.10 Fosun Pharma
  56. 7.10.1 Fosun Pharma Company Information
  57. 7.10.2 Fosun Pharma Business Overview
  58. 7.10.3 Fosun Pharma Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Fosun Pharma Ondansetron Product Portfolio
  60. 7.10.5 Fosun Pharma Recent Developments
  61. 7.11 Harbin Medisan
  62. 7.11.1 Harbin Medisan Company Information
  63. 7.11.2 Harbin Medisan Business Overview
  64. 7.11.3 Harbin Medisan Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Harbin Medisan Ondansetron Product Portfolio
  66. 7.11.5 Harbin Medisan Recent Developments
  67. 7.12 CTX Lifesciences
  68. 7.12.1 CTX Lifesciences Company Information
  69. 7.12.2 CTX Lifesciences Business Overview
  70. 7.12.3 CTX Lifesciences Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 CTX Lifesciences Ondansetron Product Portfolio
  72. 7.12.5 CTX Lifesciences Recent Developments
  73. 7.13 Pfizer
  74. 7.13.1 Pfizer Company Information
  75. 7.13.2 Pfizer Business Overview
  76. 7.13.3 Pfizer Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Pfizer Ondansetron Product Portfolio
  78. 7.13.5 Pfizer Recent Developments
  79. 7.14 Viatris
  80. 7.14.1 Viatris Company Information
  81. 7.14.2 Viatris Business Overview
  82. 7.14.3 Viatris Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Viatris Ondansetron Product Portfolio
  84. 7.14.5 Viatris Recent Developments
  85. 7.15 Dr. Reddy's Laboratories
  86. 7.15.1 Dr. Reddy's Laboratories Company Information
  87. 7.15.2 Dr. Reddy's Laboratories Business Overview
  88. 7.15.3 Dr. Reddy's Laboratories Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Dr. Reddy's Laboratories Ondansetron Product Portfolio
  90. 7.15.5 Dr. Reddy's Laboratories Recent Developments
  91. 7.16 Aurobindo Pharma
  92. 7.16.1 Aurobindo Pharma Company Information
  93. 7.16.2 Aurobindo Pharma Business Overview
  94. 7.16.3 Aurobindo Pharma Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Aurobindo Pharma Ondansetron Product Portfolio
  96. 7.16.5 Aurobindo Pharma Recent Developments
  97. 7.17 Zydus Lifesciences
  98. 7.17.1 Zydus Lifesciences Company Information
  99. 7.17.2 Zydus Lifesciences Business Overview
  100. 7.17.3 Zydus Lifesciences Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Zydus Lifesciences Ondansetron Product Portfolio
  102. 7.17.5 Zydus Lifesciences Recent Developments
  103. 7.18 Lupin
  104. 7.18.1 Lupin Company Information
  105. 7.18.2 Lupin Business Overview
  106. 7.18.3 Lupin Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Lupin Ondansetron Product Portfolio
  108. 7.18.5 Lupin Recent Developments
  109. 7.19 Hikma Pharmaceuticals
  110. 7.19.1 Hikma Pharmaceuticals Company Information
  111. 7.19.2 Hikma Pharmaceuticals Business Overview
  112. 7.19.3 Hikma Pharmaceuticals Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Hikma Pharmaceuticals Ondansetron Product Portfolio
  114. 7.19.5 Hikma Pharmaceuticals Recent Developments
  115. 7.20 Fresenius Kabi
  116. 7.20.1 Fresenius Kabi Company Information
  117. 7.20.2 Fresenius Kabi Business Overview
  118. 7.20.3 Fresenius Kabi Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Fresenius Kabi Ondansetron Product Portfolio
  120. 7.20.5 Fresenius Kabi Recent Developments
  121. 7.21 Baxter Pharmaceuticals
  122. 7.21.1 Baxter Pharmaceuticals Company Information
  123. 7.21.2 Baxter Pharmaceuticals Business Overview
  124. 7.21.3 Baxter Pharmaceuticals Ondansetron Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Baxter Pharmaceuticals Ondansetron Product Portfolio
  126. 7.21.5 Baxter Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Ondansetron Market Size by Type
  2. 8.1.1 North America Ondansetron Revenue by Type (2021-2032)
  3. 8.1.2 North America Ondansetron Sales by Type (2021-2032)
  4. 8.1.3 North America Ondansetron Price by Type (2021-2032)
  5. 8.2 North America Ondansetron Market Size by Application
  6. 8.2.1 North America Ondansetron Revenue by Application (2021-2032)
  7. 8.2.2 North America Ondansetron Sales by Application (2021-2032)
  8. 8.2.3 North America Ondansetron Price by Application (2021-2032)
  9. 8.3 North America Ondansetron Market Size by Country
  10. 8.3.1 North America Ondansetron Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Ondansetron Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Ondansetron Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Ondansetron Market Size by Type
  2. 9.1.1 Europe Ondansetron Revenue by Type (2021-2032)
  3. 9.1.2 Europe Ondansetron Sales by Type (2021-2032)
  4. 9.1.3 Europe Ondansetron Price by Type (2021-2032)
  5. 9.2 Europe Ondansetron Market Size by Application
  6. 9.2.1 Europe Ondansetron Revenue by Application (2021-2032)
  7. 9.2.2 Europe Ondansetron Sales by Application (2021-2032)
  8. 9.2.3 Europe Ondansetron Price by Application (2021-2032)
  9. 9.3 Europe Ondansetron Market Size by Country
  10. 9.3.1 Europe Ondansetron Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Ondansetron Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Ondansetron Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Ondansetron Market Size by Type
  2. 10.1.1 China Ondansetron Revenue by Type (2021-2032)
  3. 10.1.2 China Ondansetron Sales by Type (2021-2032)
  4. 10.1.3 China Ondansetron Price by Type (2021-2032)
  5. 10.2 China Ondansetron Market Size by Application
  6. 10.2.1 China Ondansetron Revenue by Application (2021-2032)
  7. 10.2.2 China Ondansetron Sales by Application (2021-2032)
  8. 10.2.3 China Ondansetron Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Ondansetron Market Size by Type
  2. 11.1.1 Asia Ondansetron Revenue by Type (2021-2032)
  3. 11.1.2 Asia Ondansetron Sales by Type (2021-2032)
  4. 11.1.3 Asia Ondansetron Price by Type (2021-2032)
  5. 11.2 Asia Ondansetron Market Size by Application
  6. 11.2.1 Asia Ondansetron Revenue by Application (2021-2032)
  7. 11.2.2 Asia Ondansetron Sales by Application (2021-2032)
  8. 11.2.3 Asia Ondansetron Price by Application (2021-2032)
  9. 11.3 Asia Ondansetron Market Size by Country
  10. 11.3.1 Asia Ondansetron Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Ondansetron Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Ondansetron Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Ondansetron Market Size by Type
  2. 12.1.1 SAMEA Ondansetron Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Ondansetron Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Ondansetron Price by Type (2021-2032)
  5. 12.2 SAMEA Ondansetron Market Size by Application
  6. 12.2.1 SAMEA Ondansetron Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Ondansetron Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Ondansetron Price by Application (2021-2032)
  9. 12.3 SAMEA Ondansetron Market Size by Country
  10. 12.3.1 SAMEA Ondansetron Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Ondansetron Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Ondansetron Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Ondansetron Value Chain Analysis
  2. 13.1.1 Ondansetron Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Ondansetron Production Mode & Process
  6. 13.2 Ondansetron Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Ondansetron Distributors
  9. 13.2.3 Ondansetron Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst